Profile data is unavailable for this security.
About the company
Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticala and Consumer Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Company is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment has been moved to Cinven which operates as an independent company called Envu.
- Revenue in USD (TTM)54.79bn
- Net income in USD5.16bn
- Incorporated1952
- Employees102.30k
- LocationBayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
- Phone+49 214301
- Fax+49 2 143066328
- Websitehttps://www.bayer.de/
Mergers & acquisitions
| Acquired company | BAYX.N:GER since announced | Transaction value |
|---|---|---|
| Blackford Analysis Ltd | -0.37% | -- |
| Targenomix GmbH | 13.01% | -- |
| Gloryfeel GmbH | 12.08% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DuPont de Nemours Inc | 14.18bn | 1.16bn | 36.83bn | 28.00k | 32.39 | 1.48 | 14.78 | 2.60 | 2.29 | 3.63 | 27.84 | 50.15 | 0.3148 | 3.54 | 5.49 | 506,571.40 | 2.71 | -0.2227 | 3.11 | -0.2892 | 35.05 | 31.60 | 8.62 | -1.61 | 1.99 | 5.11 | 0.3173 | -- | 16.15 | -19.13 | 172.14 | -15.09 | -25.20 | -26.30 |
| Iqvia Holdings Inc | 14.31bn | 1.18bn | 43.37bn | 85.00k | 38.00 | 8.11 | 19.47 | 3.03 | 6.15 | 6.15 | 74.43 | 28.78 | 0.593 | -- | 5.76 | 181,101.30 | 4.94 | 1.77 | 6.25 | 2.14 | 34.72 | 34.30 | 8.34 | 3.64 | -- | 5.16 | 0.6986 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| Bayer AG (ADR) | 54.79bn | 5.16bn | 60.29bn | 102.30k | 11.92 | 1.36 | 6.03 | 1.10 | 1.31 | 1.31 | 13.94 | 11.54 | 0.4028 | 1.60 | 4.74 | 549,875.20 | 3.82 | -1.37 | 5.10 | -1.77 | 62.32 | 59.99 | 9.48 | -3.73 | 0.7724 | 4.89 | 0.5193 | -- | 6.48 | 4.76 | 106.42 | -23.20 | 0.2547 | -5.52 |
| Moderna Inc | 21.39bn | 11.77bn | 66.96bn | 2.70k | 6.30 | 3.75 | 5.53 | 3.13 | 27.65 | 27.65 | 50.69 | 46.49 | 0.9106 | 2.93 | 7.33 | 7,922,222.00 | 50.09 | 41.17 | 77.88 | 66.78 | 79.20 | -- | 55.00 | 52.35 | 1.80 | -- | 0.0599 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
| Zoetis Inc | 8.01bn | 2.07bn | 78.21bn | 12.10k | 38.35 | 16.79 | 30.95 | 9.77 | 4.38 | 4.38 | 16.94 | 10.00 | 0.5849 | 1.14 | 6.84 | 661,735.60 | 15.08 | 13.79 | 17.93 | 16.04 | 70.19 | 68.75 | 25.78 | 23.94 | 1.48 | 12.19 | 0.5847 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Vertex Pharmaceuticals Incorporated | 8.70bn | 3.27bn | 81.44bn | 3.90k | 25.04 | 6.25 | 23.83 | 9.36 | 12.67 | 12.67 | 33.69 | 50.77 | 0.5934 | 2.89 | 7.00 | 2,230,913.00 | 22.32 | 18.01 | 26.40 | 21.87 | 88.00 | 87.77 | 37.62 | 29.17 | 4.55 | 32.16 | 0.0328 | 0.00 | 22.06 | 34.79 | -13.63 | -- | 32.96 | -- |
| Regeneron Pharmaceuticals Inc | 13.71bn | 5.37bn | 82.55bn | 10.37k | 15.99 | 3.85 | 14.48 | 6.02 | 47.40 | 47.40 | 120.98 | 197.05 | 0.534 | 0.8967 | 2.49 | 1,322,357.00 | 20.92 | 25.64 | 24.00 | 29.99 | 85.39 | 88.51 | 39.17 | 39.11 | 4.52 | 20.54 | 0.1119 | -- | 89.14 | 27.02 | 129.86 | 55.24 | 1.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Dec 2022 | 2.04m | 0.05% |
| Pacer Advisors, Inc.as of 05 Jan 2023 | 801.80k | 0.02% |
| Altrius Capital Management, Inc.as of 30 Sep 2022 | 418.28k | 0.01% |
| McGinn Investment Management, Inc.as of 30 Sep 2022 | 341.00k | 0.01% |
| BlackRock Advisors LLCas of 20 Apr 2022 | 265.64k | 0.01% |
| Arrowstreet Capital LPas of 30 Nov 2022 | 144.86k | 0.00% |
| Envestnet Asset Management, Inc.as of 30 Nov 2022 | 141.26k | 0.00% |
| Cambiar Investors LLCas of 30 Nov 2022 | 135.00k | 0.00% |
| Olive Street Investment Advisers LLCas of 25 Jan 2023 | 82.17k | 0.00% |
| Yousif Capital Management LLCas of 31 Dec 2022 | 65.70k | 0.00% |
